Prevention of CR-POPF in PD With the Technique of Connexion the Pancreatic Duct to Jejunum Stented (CONDUCTJE-ST).

From January 2018 to February 2020, a PD was performed with the CONDUCTJE-ST technique in 50 consecutive patients by the same surgical team, whose main surgeon has make more than 250 PD, in our Hepatobiliopancreatic Surgery and Liver Transplantation Unit. The study was carried out in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of the Community of Aragon (CEICA), Act No. 16/2018. Patient care and study conduct complied with good clinical practices and written informed consent was obtained from each patient.

The selection of patients for surgery was decided collectively by the Multidisciplinary Committee for Tumors of the Liver, Bile ducts and Pancreas of our hospital. No patient received neoadjuvant treatment.

Technical aspects:

Patients received general anesthesia and multimodal pain therapy with an epidural catheter. All patients underwent resection with curative intent, performing PD with antrectomy and standard lymphadenectomy. Immediately after sectioning the pancreas at the level of the isthmus-body, a tissue slice is biopsied from the section margin. In the reestablishment of digestive continuity, we successively perform four reconstructions. The restoration of the flow of pancreatic juice from the corporocaudal remnant towards the intestine was carried out with the technique of "connection of the pancreatic duct to the jejunum with stent (CONDUCTJE-ST)".

Patient characteristics:

All study data were prospectively recorded. The demographic characteristics, comorbidities, clinical manifestations of the disease and intraoperative parameters were analyzed. During the intervention, the texture of the remaining pancreatic parenchyma was classified as soft or hard and the diameter of the external orifice of the main pancreatic duct was measured after transection; these data were distributed by disease pathology as confirmed by final histological assessment.

Patient outcome and follow-up. The primary endpoint of the study was the incidence of CR-POPF. No patient received prophylactic or therapeutic somatostatin or its analogues. According to the 2016 updated of the ISGPS16, POPF has been defined as any volume of fluid collected in the abdominal drainage on postoperative day 3 or from this day with an amylase level 3 times higher than the normal value serum amylase. CR-POPF has been considered when the criteria for grades B or C were met, while grade A has been replaced by the denomination of biochemical leak (16).

The volume and appearance of the fluid from the abdominal drains was recorded daily. The amylase concentration in the fluid of each of the drains was analyzed on the third and sixth postoperative days, as well as before removing the drain and on any day in which there was a substantial increase in volume or change in the appearance of the fluid. The drains were removed when three requirements were met: amylase levels in the drainage fluid less than 8 twice the plasma level (normal 28-100 U / L), volume <25 ml / day, and clear appearance of the fluid.

The secondary endpoints of the study were: 1) postoperative mortality, defined as that which occurred within thirty days of the operation or during the same hospital admission; 2) postoperative complications related to the surgical technique: delayed gastric emptying (DGE), digestive and intra-abdominal hemorrhage, intra-abdominal abscesses, surgical wound infection, biliary fistula and gastrointestinal fistula; 3) days of stay in the Intensive Care Unit (ICU) and hospital, reoperations, and readmissions. The DGE and postoperative bleeding were defined according to the ISGPS29,30. The severity of complications was classified using the Clavien-Dindo system31; a severe complication was defined as grade IIIa or higher; 5) during the first year after PD: a) the incidence of exocrine pancreatic insufficiency (EPI), evaluated by the presence of steatorrhea, need for pancreatic enzyme supplements and fecal elastase determination; b) incidence of new-onset diabetes mellitus (NODM), assessed by blood glucose, glycated hemoglobin A1c and need for insulin or oral antidiabetics; c) overall survival and by pathologies and, in the case of malignant processes, disease-free survival, at 3, 6, 9 and 12 months after PD.